Prevalence and structure of fatty liver disease of varying etiology at the rural therapeutic stretch
https://doi.org/10.31146/1682-8658-ecg-176-4-65-71
Abstract
The aim of the research: Examination of the prevalence, bending, age and sex structure of fatty liver lesions (FL) of diff erent etiology in rural therapeutic area.
Materials and methods: 1152 person (73.5%) from 1568 the population of the rural therapeutic area, came to the examination.
Results: Free fatty liver disease (NAFLD) was revealed at 21.4%, alcoholic liver disease (ALD)-24.0% of the rural population (p>0.05). FL associated with viral hepatitis B and/or C, detected at 1.7%; toxic hepatitis — 1 man — 0,09% among the surveyed. Prevalence of NAFLD was 220.1; FLD — 246.0; FL associated with viral hepatitis B and/or C — 17.4; FL amid toxic hepatitis — 0.9 on 1000 population rural therapeutic plot. In NAFLD, the ratio between men and women was 1 : 4.3 (p <0.001). Liver steatosis signifi cantly prevailed in the nosological structure of NAFLD (p <0.001), it was in 225 (91.1%), steatohepatitis in 20 (8.1%), cirrhosis in 2 (0.8%) people, no gender diff erences were revealed (p>0.05). Almost half the patients accounted for working age (48.2%): men — 51.1%, women — 47.5%; diff erences are not signifi cant (p> 0.05). In ALD the ratio between men and women was 1 : 1.4 (p>0.05). The nosological structure of ALD: liver steatosis in 167 (60.5%), steatohepatitis in 62 (22.5%), cirrhosis in 47 (17.0%) people. Most patients with ALD, both men (73.0%) and women (75.2%), were of working age (p <0.001). FL among persons with positive markers of viral hepatitis B and/or C20 have been identifi ed (1.7% of the total number surveyed) people: men — 9 (45.0%), female — 11 (55.0%) (p>0.05). Nosological structure of FL: liver steatosis — 10 (50.0%), steatohepatitis — 2 (10.0%), liver cirrhosis — 7 (35.0%), liver cancer — 1 (5.0%).
About the Authors
N. V. Mikhailova
Usolsk City Hospital
Russian Federation
physician district
665459, Usolye-Sibirskoye, Kuibysheva str., 4
Russian Federation
physician district
665459, Usolye-Sibirskoye, Kuibysheva str., 4
I. L. Petrunko
Irkutsk State Medical Academy of Postgraduate Education — Branch Campus of the Russian Medical Academy of Continuing Professional Education
Russian Federation
Head of the Department of medical examination, Professor, MD
Russian Federation
Head of the Department of medical examination, Professor, MD
References
1. Lazebnik L. B., Radchenko V. G., Golovanova Е. V., et al. Nonalcoholic fatti liver disease: clinic, diagnostics, treatment (recommendations for therapists, 2ndedition). Experimental and Clinical Gastroenterology, 2017; 138 (02): 22–37.
2. WHO. Globalstatusreport: Alcoholandhealth. – 2014. http://www.who.int/substance_abuse/publications/globalalcoholreport/en (Accessed 20 February 2018).
3. Younossi Z.M., Stepanova M., Affendy M. et al. Changes in the prevalence of major chronic liver disease in the United States from 1998 to 2008.Clinical gastroenterology and hepatology. Russian edition, 2011;(05): 261–267.
4. Clark J. M. The epidemiology of nonalcoholic fatty liver disease adults. J. Clin Gastroenterol. 2006, no.40, pp. 5–10.
5. Ivashkin V. T., Drapkina O. M., Mayev I. V., et al. Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results. Ross J Gastroenterol Gepatol Koloproktol. 2015; 25 (06): 31–41.
6. Plotnikova E. Yu., Talickaja E. A., Krasnova M. V., Krasnov K. A. Steatohepatit – variant lekarstvennogo porageniy [Steatohepatitis-drug option defeats]. Farmateka. –Farmateka, 2008. vol. 6, no. 259. pp. 68–72.
7. Brea A., Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Journal Cardiol. 2013, no.167(4), p. 17.
8. Stravitz R.T., Sanyal A. J. Drug-induced steatohepatitis. Clin. Liver Dis. 2003, no. 7(435), p. 51.
9. Grieko A., Forgione A., Miele L., et al. Fatty liver and drugs. European Review for Medical and Pharmacological Sciences. 2005, no.9 (261), Р. 63.
10. Clinical Practical Guidelines: Management of Alcoholic Liver Disease European Association for the Study of the Liver (EASL), 2012. J. of Hepatology. 2012, Vol. 57, P. 399–420/
11. O`Shea R. S., Dasarathy S., McCullough A. J. et al. Alcoholic liver disease. AASLD practice guidelines. Hepatology. 2010, Vol. 51, no. 1, pp. 307–328.
12. Podymova S. D. Alkogolnaja bolezn pecheni: Mehanizmy progressirovanija, patogenetiheskay terapiy [Alcoholic liver disease: mechanisms of progression, pathogenetic therapy]. Available at: https://www.lvrach.ru/2001/06–06/4528796/ (accessed 23 August 2017).
13. Ametov A. S., Prudnikova M. A. Diagnostika I lehenie nealcogolnoi jirovoi bolezni peheni u pacientov s saharnim diabetom tipa 2: sovremennii vzglyd na problemu [Diagnosis and treatment of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: a modern view on the problem]. Endokrinologiy: novosti, mneniy, obuсhenie. – Endocrinology: news, views, training. 2016, no. 3, pp. 37–45.
14. Balukova E. V., Uspensky Y. P. Nealkogolnay jirovay bolezn peheni I metaboliheskii sindrom [Non-alcoholic fatty liver disease and metabolic syndrome]. Gastroenterologiy – Gastroenterology. 2014. no. 1, pp. 45–48.
15. FrithJ., Day C. P., HendersonE., Burt A. D., Newton J. L. Non-alcoholic fatty liver disease in older PEOPLE. Gerontology. 2009, no.55(6), pp. 607–613.
16. Bellentani S., Scaglioli F., Marino M., Bedogni G. Epidemiology of non–alcoholic fatty liver disease. Dig. Dis. 2010, no.28, pp. 155–161.
17. Komova A., Maevskaya M., Ivashkin V. Prevalence of Liver Disease in Russia’s Largest City: A Population based Study. Am J Clin Med Res. 2014;2(5):99–102.
18. Tkachenko L. I., Maleev V. V. Liver steatosis in patients with chronic viral hepatitis B. Kazan medical journal. 2014; 95 (01): 35–41.
19. Castera L. Steatosis, insulin resistance and fibrosis progression in chronic hepatitis. Minerva Gastroenterol. Dietol. 2006, Vol. 52, pp. 125–134.
20. Maevskaya M. V., Bakulin I. G., Chirkov A. A., Lucina E.O, Lunkov V. D. Alcohol abuse among gastroenterological patients. Ros J Gastroenterol Hepatol Koloproc. 2016;26(04): 24–35.
21. Ballestri S., Nascimbeni F., Baldelli E. et al. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. Adv Ther. 2017, Vol. 34(6), pp. 1291–1326.
22. Yeremina E. U. Alcoholic liver disease. Archives of internal medicine. 2012;6 (08):50– 54.
23. Lonardo A., Bellentani S., Argo C. K. et al. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis. – 2015. vol. 47, no. 12, pp. 997–1006.
Review
For citations:
Mikhailova N.V., Petrunko I.L. Prevalence and structure of fatty liver disease of varying etiology at the rural therapeutic stretch. Experimental and Clinical Gastroenterology. 2020;174(4):65-71. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-176-4-65-71
Views:
462
Email this article 